Algeria leader back to Germany for COVID-19-linked treatment

2 mins read
How major US stock indexes fared Tuesday

ALGIERS, Algeria (AP) — Algerian President Abdelmadjid Tebboune returned Sunday to Germany, where he spent two months for treatment of a COVID-19 infection, this time to treat a related foot problem, the presidency announced.

The complication from the coronavirus infection was initially to be treated during his stay, cut short by pressing presidential issues at home, the statement said.

Tebboune, 75, disappeared from the radar of his North African nation after leaving for treatment Oct. 28. The name of the clinic caring for him was never announced and he spoke to the nation only shortly before his return Dec. 29.

Before boarding a plane to Germany on Sunday, he said he would undergo an operation as part of follow-up care, describing the intervention as “light” and saying he would follow national issues during his brief absence. He provided no details on the operation.

Tebboune thanked officials “for their mobilization, firstly the army.”

Tebboune was elected president in December, months after former President Abdelaziz Bouteflika was pushed from power in April 2019 by pro-democracy demonstrators and the army chief after 20 years at the helm.

Analysts Hate These 12 Stocks

When a single Wall Street analyst downgrades one of your stocks, you might think they are just having a bad day or have an incorrect investment thesis. One downgrade typically won’t have a significant impact on the price of one of your stocks, but what if analysts repeatedly downgraded a company over the last 30, 60, or 90 days? You would know something is seriously wrong.

Today, we invite you to take a free exclusive look at our up-to-the-minute list of 12 “Most Downgraded” stocks. These are true strong sell stocks. Analysts are abandoning them in droves and issuing rare downgrades and sell ratings. If any of these stocks are lurking around in your portfolio, seriously consider whether or not they still belong in your portfolio.

View the “Analysts Hate These 12 Stocks”.